Review Form 1.6

Journal Name:	**Journal of Cancer and Tumor International**
Manuscript Number:	**Ms_JCTI_87519**
Title of the Manuscript:	**Prevention of adjuvant treatment induced cardiotoxicity in Egyptian breast cancer patients: a randomized prospective study**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(https://www.journaljcti.com/index.php/JCTI/editorial-policy)

PART 1: Review Comments

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**The article is a great one showing good results in an important era that make medical oncologists changing a lot of protocols due to cardiac toxicity but I noted :** **1.Small sample of patients although the rate of breast cancer is so high worldwide so we can obtain a large sample of patients.** **2. the study done between 2015-2016 so too long time passed with follow up only for one year so why the delay?** **3. was the study contain the protocol of trastuzumab /pergitta or not and if yes , is there a difference in cardiotoxicity or not significant?**	
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	**Essam Elshiekh**
Department, University & Country	**Tanta Cancer Center, Egypt**